老虎证券

BRIEF-Innovent Biologics Says Co And Takeda Will Co-Develop IBI363 (Pd-1/Il-2Α-Bias) Globally And Co-Commercialize It In U.S.

Reuters
10/22
BRIEF-<a href="https://laohu8.com/S/IVBIY">Innovent Biologics</a> Says Co And Takeda Will Co-Develop IBI363 (Pd-1/Il-2Α-Bias) Globally And Co-Commercialize It In U.S.

Oct 22 (Reuters) - Innovent Biologics Inc 1801.HK:

  • INNOVENT AND TAKEDA WILL CO-DEVELOP IBI363 PD-1/IL-2Α-BIAS) GLOBALLY AND CO-COMMERCIALIZE IT IN U.S.

  • WILL RECEIVE $1.2 BILLION UPFRONT PAYMENT, INCLUDING STRATEGIC EQUITY INVESTMENT OF $100 MILLION BY WAY OF SUBSCRIPTION

  • CO ALSO ELIGIBLE FOR POTENTIAL MILESTONES TOTALING UP TO $10.2 BILLION

Further company coverage: 1801.HK

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10